Prime Medicine Discloses $61.2M Cash as It Launches $125M Offering
PRME sits 42% above its 52-week low of $2.67.
Summary
Prime Medicine disclosed preliminary September 30, 2026 cash of about $61.2 million (excluding $13.7 million restricted) alongside an updated corporate presentation, filed the same day it launched a $125.0 million underwritten stock offering.
Key Events · Financing and Capital Events · PRME
-
Preliminary Q3 Cash of $61.2M
Estimated cash, cash equivalents and short-term investments stood at approximately $61.2 million as of September 30, 2026, excluding approximately $13.7 million of restricted cash; the figures are unaudited and were not reviewed by PricewaterhouseCoopers.
-
$125M Offering Launched Same Day
The 8-K lands alongside a $125.0 million underwritten common stock offering with a 30-day option for up to $18.75 million more; pricing terms are not stated in this filing.
-
Cash Position Down From $95.1M
Cash fell from $95.1 million at June 30, 2026 (per the prior 10-Q) to about $61.2 million at September 30, reinforcing the going-concern pressure that makes the raise necessary.
-
2027 Data and BLA Milestones Reiterated
The updated November 2026 presentation keeps initial clinical data for PM577a (Wilson disease) and PM647 (AATD) in 2027 and a PM359 BLA submission in CGD planned for the first half of 2027.
Analysis · PRME · Life Sciences
The $125.0 million underwritten offering announced the same day is the headline, but the reason behind it sits in the cash balance: roughly $61.2 million of cash, equivalents and short-term investments at September 30, 2026 (plus $13.7 million restricted), against a prior going-concern warning and a burn rate that had already drawn cash down to $95.1 million at June 30. Without the raise, runway was short. This 8-K is the disclosure vehicle, pairing the preliminary cash figure with an updated corporate deck that reiterates PM577a and PM647 initial data in 2027 and a PM359 BLA submission planned for the first half of 2027. Dilutive, yes, but it is the capital that keeps those 2027 readouts funded; the key question is the offering price relative to the prevailing market, which this filing does not state.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRME was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.4M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.